Results 11 to 20 of about 276,570 (260)

Insights into the interaction of CD4 with anti-CD4 antibodies

open access: yesImmunobiology, 2017
Knowledge about the mechanism by which some antibodies can block HIV-1 entry is critical to our understanding of their function and may offer new avenues for controlling the adhesion of HIV-1 to the host cells. While much progress has been made, this mechanism remains unclear.
Van-Chien, Bui, Thi-Huong, Nguyen
openaire   +2 more sources

Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism. [PDF]

open access: yes, 2013
CD4(+) T-cell loss is the hallmark of HIV-1 infection. CD4 counts fall more rapidly in advanced disease when CCR5-tropic viral strains tend to be replaced by X4-tropic viruses.
de Lara, C   +27 more
core   +1 more source

Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods. [PDF]

open access: yes, 2011
BACKGROUND: Survival analysis using time-updated CD4+ counts during antiretroviral therapy is frequently employed to determine risk of clinical events.
Lewis, James J   +31 more
core   +1 more source

Epidemiology and results of the first line therapy for HIV-related Hodgkin lymphoma

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2022
Introduction. The risk of developing Hodgkin lymphoma (HL) with HIV infection is higher than in the general population, and the course of the disease itself is more aggressive.
A. M. Chekalov   +17 more
doaj   +1 more source

Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection [PDF]

open access: yes, 2007
Background. CD4+ T cell help is critical in maintaining antiviral immune responses and such help has been shown to be sustained in acute resolving hepatitis C.
Paul Klenerman   +178 more
core   +2 more sources

Laboratory biomarkers and immunological modulation of sintilimab in gastric cancer: A meta-analysis focused on tumor markers and T-cell subsets [PDF]

open access: yesJournal of Medical Biochemistry
Background: Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored.
Zhang Xian   +6 more
doaj   +1 more source

Viewpoint: Why do we need a point-of-care CD4 test for low-income countries? [PDF]

open access: yes, 2010
In this paper, we discuss the reasons why we urgently need a point-of-care (POC) CD4 test, elaborate the problems we have experienced with the current technology which hampers CD4-count coverage and highlight the ideal characteristics of a universal CD4 ...
Harries, AD   +14 more
core   +1 more source

A proposed model of the potential TCR-pMHC-II-CD4-Env38 complex.

open access: yes, 2023
The TCR-pMHC-II-CD4-Env38 complex formed in the immune synapse structure between MHC+Env38+ APC and CD4+ T cell during APC-initiated CD4+ T cell activation.
Jun Bai (398174)   +6 more
core   +1 more source

CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. [PDF]

open access: yes, 2006
BACKGROUND: Patients accessing antiretroviral treatment (ART) programmes in sub-Saharan Africa frequently have very advanced immunodeficiency. Previous data suggest that such patients may have diminished capacity for CD4 cell count recovery.
Myer, Landon   +12 more
core   +2 more sources

Therapeutic effects of fire-needling combined with halomethasone cream on stable vitiligo and its effect on CD4+, CD8+ and CD4+/CD8+ levels

open access: yesPifu-xingbing zhenliaoxue zazhi, 2022
Objective To evaluate the clinical efficacy of fire needling combined with halomethasone cream in the treatment of stable vitiligo, and its impact on the levels of CD4+, CD8+ and CD4+/CD8+, providing a rationale for the clinical use of fire needling ...
Nan TANG   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy